Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.

Sponsor
AstraZeneca
Study ID
NCT03219970
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To assess the efficacy of single-agent osimertinib in relation to EGFR T790M mutant allele fraction (AF) in a real-world setting.

Key Dates

Start date
Sep 5, 2017
Status verified
Sep 2021
Primary completion
Oct 28, 2020
Completion
Oct 28, 2020

Study Design

Enrollment
156 participants (actual)

Arms

  • Arm: EGFR T790M positive NSCLC patients
    Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI treatment.

Primary Outcome Measure

Association between T790M mutant status and overal survival [ Time Frame: Followed up to 2 years after last patient in ]

Related Studies